View Cart (0 items)
Pharmaceutical

FDA Extends Plavix Patent by Six Months

January 25, 2011
/ Print / Reprints /
| Share More
/ Text Size+

The Associated Press reports that the makers of Plavix, the world''s second best-selling medication, will retain exclusive U.S. marketing rights to the blood thinner for an additional six months, under a decision by U.S. health regulators. Bristol-Myers Squibb and partner Sanofi-Aventis say the Food and Drug Administration granted the companies a six month patent extension for Plavix after the companies conducted extra studies of the drug in infants. The FDA program is designed to reward companies for testing drugs in children, who are typically excluded from medical studies. With the extension, the companies will be able to market the drug exclusively until May 17, 2012.

You must login or register in order to post a comment.